Skip to main content
. 2000 Oct 10;97(22):12198–12203. doi: 10.1073/pnas.220413497

Figure 2.

Figure 2

NY-ESO-1-specific cytotoxicity of CD8+ T lymphocytes of patient NW745 (lymphocytes obtained on day 127 of immunization) and patient NW903 (lymphocytes obtained on day 78 of immunization) after presensitization with the NY-ESO-1 nonamer (p157–165) (a) and the NY-ESO-1 11-mer (p157–167) (b) peptides. Target cells were T2 cells alone (white bars); T2 cells pulsed with the NY-ESO-1 9 mer (p157–165; gray bars); T2 cells pulsed with the NY-ESO-1 11 mer (p157–167; black bars); NY-ESO-1+, HLA-A2+ melanoma cell lines NW-MEL-38 (striped bars); SK-MEL-37 (checkered bars); and NY-ESO-1−, HLA-A2+ melanoma cell line NW-MEL-145 (crossed bars). The chromium-51 release assay is described in Materials and Methods. nd, not done.